350 rub
Journal Technologies of Living Systems №3 for 2013 г.
Article in number:
Comparative elisa study of metalloproteinases 2, 7, 9 and their type 2 tissue inhibitor in the tumors and plasma of gastric cancer
Keywords: MMP-2 MMP-7 MMP-9 TIMP-2 stomach cancer
Authors:
E.S. Gershtein, I.S. Stilidi, N.E. Kushlinskii, M.I. Davidov
Abstract:
Matrix metalloproteinase (MMP) 2, 7 and 9 levels were significantly increased in the tumors as compared to adjacent histologically unchanged mucosa in 80, 70 and 72% of stomach cancer patients, while the increase of type 2 tissue metalloproteinase inhibitor observed in 61% of the tumors was not statistically significant. Only MMP-7 level was increased in blood plasma of primary patients as compared to control group and was positively associated with tumor expression level of this protein. MMP-7 increase was mostly pronounced in patients with tumor invasion into lymphatic vessels. Thus, MMP-7 may be considered as a potential serologic marker of stomach cancer.
Pages: 48-52
References
  1. Gershtejjn E.S., Korotkova E.A., SHHerbakov A.M. i soavt. Matriksnye metalloproteinazy 7 i 9 i ikh tkanevye ingibitory 1 i 4 tipa v opukholjakh i plazme krovi bolnykh rakom tolstojj kishki // Bjulleten ehksperimentalnojj biologii i mediciny. 2007. V. 143. № 3. S. 438 - 441.
  2. Ajisaka H., Yonemura Y., Miwa K. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer // Hepatogastroenterology. 2004. V. 51. № 57. P.900 - 905.
  3. Deryugina E.I., Quigley J.P.Matrix metalloproteinases and tumor metastasis // Cancer Me-tastasis Rev. 2006. V. 25. № 1. P. 9 - 34.
  4. Elnemr A., Yonemura Y., Bandou E. et al.Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer // Gastric Cancer. 2003. V. 6. № 1. P. 30-38.
  5. Kubben F.J., Sier C.F., van Duijn W. et al.Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer // Br. J. Cancer. 2006. V. 94. № 7. P. 1035 - 1040.
  6. Mrena J., Wiksten J.P., Nordling S. et al.MMP-2  but not MMP-9 associated with COX-2 and survival in gastric cancer //J. Clin. Pathol. 2006. V. 59. № 6.  P. 618 - 623.
  7. Nelson A.R., Fingleton B., Rothen­berg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications // J. Clin. Oncol. 2000. V. 18. № 5.  P. 1135 - 1149.
  8. Ramnath N., Creaven P.J.Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6. № 2. P. 96 ? 102.
  9. Shim K.N., Jung S.A., Joo Y.H., Yoo K.Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer // J. Gastroenterol. 2007. V. 42. № 2. P. 120 - 128.
  10. Sounni N.E., Janssen M., Foidart J.M., Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis // Matrix Biol. 2003. V. 22. № 1. P. 55 - 61.
  11. Watson S.A., Morris T.M., Collins H.M. et al. Inhi-
    bition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA // Br. J. Cancer. 1999. V. 81. № 1. P. 19 ? 23.
  12. Westermarck J., Kahari V.M. Regulation of  matrix metalloproteinase expression in tumor invasion // Faseb J. 1999. V. 13. № 8.  P. 781 - 792.
  13. Wu C.Y., Wu M.S., Chen Y.J. et al.Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer // Eur. J. Cancer. 2007. V. 43. № 4. P. 799 - 808.
  14. Wu C.Y., Wu M.S., Chiang E.P. et al.Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution // Clin. Cancer Res. 2007. V. 13. № 7. P. 2054 - 2060.
  15. Yonemura Y., Endo Y., Fujita H. et al. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide // J. Exp. Clin. CancerRes. 2001. V. 20.  № 2. P. 205 - 212.